Clinical Trial Update: Tislelizumab Plus Chemotherapy as First-Line Treatment for Advanced Squamous NSCLC With Brain Metastases [Phase 2]

View source ↗

Summary

Phase 2 trial investigating tislelizumab plus chemotherapy as first-line treatment for advanced squamous non-small cell lung cancer with brain metastases.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Brain Metastases
• Non-small Cell Lung Cancer

Drugs mentioned

• Chemotherapy (chemotherapy)
• Tislelizumab (tislelizumab)

Snippet

Sponsor: Sun Yat-sen University | Conditions: Non-Small Cell Squamous Lung Cancer, Brain Metastases | Phase 2 | Status: UNKNOWN